Pneumonia

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.  The decision was based on positive topline results from a Phase I/II proof-of-concept study, which evaluated the safety, tolerability and immunogenicity of VAX-24 in adults 18-64 years of age.  […]

Pharming Group has announced the topline results from two randomised, open label, controlled, pilot clinical trials of patients hospitalised with Covid-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the seven-point WHO ordinal scale on Day Seven.  In the US study, which had included […]

The PneumoLight campaign, in collaboration with Pfizer – and coinciding with World Pneumonia Day – will see 232 buildings and monuments from 48 different countries will be illuminated in blue. The project involves Dr. Catia Cilloniz, a researcher at the Hospital Clínic of Barcelona, the University of Barcelona (UB), the Barcelona Institute for Global Health (ISGLOBAL), […]